ESR1 and breast cancer: We suggest that induction of ER beta expression by mibolerone may play a critical regulatory role in ER-positive cells, addressing prospectively that combined agents able to potentiate ER beta and AR signalings may be useful to inhibit breast cancer cell growth and progression.